SCHEMBL2288074

SCHEMBL2288074

CCSc1ccc(S(=O)(=O)NC)cc1[N+](=O)[O-]

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 2/20 0.58
MAPT P10636 4/20 0.51
LMNA P02545 2/20 0.51
ALDH3A1 P30838 4/20 0.49
CA2 P00918 3/20 0.49
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA3 P07451 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA13 Q8N1Q1 1/20 0.47
CA14 Q9ULX7 1/20 0.47
CA5B Q9Y2D0 1/20 0.47
ALDH1A1 P00352 5/20 0.46
CCR2 P41597 1/20 0.44
EPAS1 Q99814 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL687484 0.85 VCAM1 (0.65) VCAM1MAPTLMNAALDH3A1CA2
SCHEMBL1812355 0.84 VCAM1 (0.63) VCAM1MAPTLMNAALDH3A1CA2
SCHEMBL6114282 0.82 CA2 (0.70) VCAM1MAPTCA2CA12CA1
SCHEMBL15647017 0.82 VCAM1 (0.48) VCAM1MAPTLMNACA2ALDH1A1
SCHEMBL12517843 0.78 ALDH1A1 (0.44) VCAM1MAPTLMNACA2CA12
SCHEMBL8973769 0.75 TXNRD1 (0.66) MAPTLMNAALDH1A1KMT2AGAA
SCHEMBL12067854 0.75 VCAM1 (0.69) VCAM1MAPTLMNAALDH3A1CA2
SCHEMBL23302290 0.74 PDE7A (0.54) MAPTLMNACA2ALDH1A1SMN1; SMN2
SCHEMBL11280979 0.74 VCAM1 (0.67) VCAM1MAPTLMNAALDH3A1CA2
SCHEMBL1805304 0.74 VCAM1 (0.67) VCAM1MAPTLMNAALDH3A1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120329784-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC 2012-12-27 US disclosed
US-20120329784-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC 2012-12-27 US disclosed
EP-2523559-A1 COMPOUNDS AND METHODS GlaxoSmithKline LLC (US) 2012-11-21 EP disclosed
WO-2011088027-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC (US) 2011-07-21 WO disclosed
WO-2011088027-A1 COMPOUNDS AND METHODS GLAXOSMITHKLINE LLC (US) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329784-A1 COMPOUNDS AND METHODS RB1, DHFR, NQO1 VCAM1 4110/4885MAPT 3517/4885LMNA 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.